Trinity Biotech to Begin European Pre-Pivotal Trial to Optimize its CGM Sensor

June 24, 2024

https://www.globenewswire.com/news-release/2024/06/24/2902848/8624/en/Trinity-Biotech-to-Begin-European-Pre-Pivotal-Trial-to-Optimize-its-CGM-Sensor.html

DUBLIN, June 24, 2024 (GLOBE NEWSWIRE) — Trinity Biotech plc (Nasdaq:TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced steps to advance its next generation continuous glucose monitoring (“CGM”) solution towards market launch. Since acquiring the CGM technology earlier in the year, Trinity Biotech has been working on further innovations and improvements to the original device. The Company has now received regulatory approval to conduct its initial European pre-pivotal trial that will inform the larger pivotal trial that will be required for product registration and launch.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.